Official Journal of the Italian Society of Orthopaedics and Traumatology
PRP | HA | NSAID | P | |
---|---|---|---|---|
Patients | 33 | 32 | 33 | |
Responders [no. (%)] | ||||
20% decrease WOMAC pain | 10 (30) | 0 | 0 | < 0.001 |
20% decrease WOMAC stiffness | 9 (27) | 0 | 0 | < 0.001 |
20% decrease WOMAC physical function | 8 (24) | 0 | 0 | < 0.05 |
20% decrease VAS | 5 (15) | 0 | 2(6) | < 0.001 |
Change from baseline | ||||
WOMAC pain | ||||
% change from baseline | − 20.39 | − 1.03 | − 6.4 | < 0.03 |
End of follow-up | 4.84 ± 0.7 | 5.96 ± 0.4 | 5.72 ± 0.45 | < 0.001 |
WOMAC stiffness | ||||
% change from baseline | − 16.1 | − 0.7 | 4.9 | < 0.001 |
End of follow-up | 3.45 ± 0.5 | 4.03 ± 0.3 | 4.27 ± 0.45 | < 0.002 |
WOMAC physical function | ||||
% change from baseline | − 19 | 0.3 | 0.9 | < 0.001 |
End of follow-up | 26.21 ± 0.8 | 32.65 ± 0.7 | 32.78 ± 0.73 | < 0.05 |
WOMAC total | ||||
% change from baseline | − 18.9 | 0.07 | 0.2 | < 0.001 |
End of follow-up | 34.51 ± 1.2 | 42.65 ± 0.9 | 42.78 ± 1.02 | < 0.02 |
VAS | ||||
% change from baseline | − 18.2 | 3 | − 6.4 | < 0.001 |
End of follow-up | 5.03 ± 1.7 | 6.25 ± 0.4 | 5.75 ± 0.43 | < 0.001 |